Business
Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial results on Monday, November 15, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 15, to discuss the Company's financial results and provide a general business update.\nThe live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:\nConference ID: 9558836Domestic Dial-in Number: (855) 251-6663International Dial-in Number: (281) 542-4259Live webcast: https://edge.media-server.com/mmc/p/85k2svad \nFor those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.\nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. \nSyndax Contacts\nInvestor ContactMelissa ForstArgot [email protected] 212.600.1902\nMedia ContactBenjamin [email protected] 862.368.4464\nSNDX-G\n View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-november-15-2021-301418269.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":4375,"tagName":"div"}]